Barclays
MLTX icon

Barclays’s MoonLake Immunotherapeutics MLTX Stock Holding History

Barclays’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,000
Closed -$57.4K – 5511
2025
Q3 		$57.4K Sell
8,000
-2,000
-20% -$104K ﹤0.01% 4740
2025
Q2 		$472K Buy
+10,000
New +$407K ﹤0.01% 3786

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's MLTX Position: Q1 2026 in Review

Barclays reduced its MoonLake Immunotherapeutics (MLTX) stake by 45% in Q1 2026, selling an estimated $375K and leaving 27,602 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #3172.

Barclays first reported a position in MLTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $766K in Q1 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Barclays held 27,602 shares of MoonLake Immunotherapeutics worth $515K as of Q1 2026.
  • Barclays sold 22,649 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $375K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3172 holding.
  • Barclays first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 14 quarters since.
  • Barclays's MoonLake Immunotherapeutics position peaked at $766K in Q1 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.